Ariad to gross up to $345m from stock offer to fund Iclusig commercialization
This article was originally published in Scrip
Ariad Pharmaceuticals will raise at least $300 million in an offering of 15.3 million common stock shares priced at $19.60 per share to finance sales, manufacturing and distribution of the kinase inhibitor Iclusig (ponatinib), which won US FDA approval on 14 December to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) (scripintelligence.com, 15 December 2012).
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.